Tevogen Bio™ to Study Potential Use of its T cell Technology in Epstein-Barr Virus and Multiple Sclerosis

METUCHEN, N.J.–(BUSINESS WIRE)–#EBV—Tevogen Bio, a clinical stage biotechnology company specializing in cell and gene therapies in oncology and viral infections, today announced its intention to study its proprietary off-the-shelf T cell technology to develop therapeutic solutions for multiple sclerosis (MS) by developing Epstein-Barr virus (EBV) specific CD8+ cytotoxic T lymphocytes (CTL). Multiple sclerosis is a chronic inflammatory disease of the central nervous system, for which there is currently no definitive cure.

“Recent studies on multiple sclerosis have suggested a probable link between latent infection with EBV and later onset of the inflammation that degrades the myelin sheath and causes multiple sclerosis,” said Neal Flomenberg, M.D., Chairman of Tevogen’s Scientific Advisory Board. “We look to apply our significant expertise in off-the-shelf allogeneic SARS-CoV-2 specific CD8+ cytotoxic T lymphocytes (CTLs) to explore EBV specific CTL therapy as a possible means of addressing the unmet needs of MS patients,” Flomenberg added.

“Anyone that knows someone who has been impacted by this debilitating disease understands the importance of advancing science to develop pathways to alleviate the suffering from MS,” said Tevogen CEO Ryan Saadi, M.D., M.P.H. “I’m hopeful that our disruptive T cell technology will eventually offer accessible immunotherapies to millions suffering from viral infections, cancers and other diseases with high unmet need.”

About Tevogen’s Investigational T Cell Therapy for COVID-19

Tevogen’s investigational T cell therapy for COVID-19, TVGN-489, is currently undergoing proof of concept clinical trial at Jefferson University Hospitals in Philadelphia. Trial details are available at Clinical Trials – Tevogen.

TVGN-489 is a highly purified, SARS-CoV-2-specific cytotoxic CD8+ T lymphocyte product, which detects targets spread across the entire viral genome. These targeted CTLs are expected to recognize and kill off virally infected cells, allowing the body to replace them with healthy, uninfected cells. TVGN-489 demonstrated strong activity against SARS-CoV-2 targets in preclinical studies.

About Tevogen Bio

Tevogen Bio is driven by a team of distinguished scientists and highly experienced biopharmaceutical leaders who have successfully developed and commercialized multiple franchises. Tevogen’s leadership believes that accessible personalized immunotherapies are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation in the post-pandemic world.

Forward Looking Statements

This press release contains certain forward-looking statements relating to Tevogen Bio™ Inc.’s (the “Company”) development and patient access of its innovations in infectious diseases and oncology. These statements are based on management’s current expectations and beliefs as of the date of this release and are subject to a number of factors which involve known and unknown risks, delays, uncertainties and other factors not under the company’s control which may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations implied by these forward-looking statements. In any forward-looking statement in which the Company expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These factors include results of current or pending clinical trials, risks associated with intellectual property protection, financial projections, sales, pricing and actions by the FDA/EMA. The Company undertakes no obligation to update the forward-looking statements or any of the information in this release, or provide additional information, and expressly disclaims any and all liability and make no representations or warranties in connection herewith or with respect to any omissions herefrom.

Contacts

Media:

Katelyn Joyce

Corporate Communications Lead

[email protected]